Franklin Resources
TARA icon

Franklin Resources’s Protara Therapeutics TARA Stock Holding History

Franklin Resources’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-350,010
Closed -$3.41M – 2499
2021
Q2 		$3.41M Hold
350,010
– – ﹤0.01% 1232
2021
Q1 		$5.51M Hold
350,010
– – ﹤0.01% 1086
2020
Q4 		$8.47M Buy
350,010
+10
+0% +$216 ﹤0.01% 994
2020
Q3 		$5.89M Buy
+350,000
New +$8.12M ﹤0.01% 1018

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Franklin Resources's TARA Position: Q3 2021 in Review

Franklin Resources sold out of Protara Therapeutics (TARA) in Q3 2021, closing a stake of 350,010 shares — an estimated $3.41M sold.

Franklin Resources first reported a position in TARA in Q3 2020 and held it in 4 quarters. The position peaked at $8.47M in Q4 2020. 36 funds tracked by Wall St. Rank hold TARA as of Q3 2021.

  • Franklin Resources reported no remaining Protara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Franklin Resources sold 350,010 Protara Therapeutics shares in Q3 2021, an estimated $3.41M.
  • Franklin Resources first reported a position in Protara Therapeutics in Q3 2020 and held it in 4 quarters.
  • Franklin Resources's Protara Therapeutics position peaked at $8.47M in Q4 2020.
  • 36 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2021.

Based on Franklin Resources's 13F filing for Q3 2021, filed 12 Nov 2021.